Analytical Data
-
Gene name
VEGFR-2
- Application
-
Alternative Names
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35968
-
Expression Region
Asn46~Thr320
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) is a key receptor in the vascular system, primarily involved in angiogenesis, the process by which new blood vessels form from pre-existing ones. This receptor is activated by binding to its primary ligand, VEGF, which plays a pivotal role in physiological and pathological processes, including tumor growth and metastasis. The study of VEGFR-2 is crucial due to its implications in cancer therapy, where its overexpression is commonly associated with malignant progression and poor patient outcomes. Researchers have been focusing on developing recombinant VEGFR-2 proteins to better understand its structure, function, and interactions within signaling pathways. These recombinant proteins serve as critical tools for elucidating the mechanisms of angiogenesis and identifying potential therapeutic targets. By generating VEGFR-2 in a heterologous expression system, scientists can produce large quantities of the protein for biochemical assays and structural studies. This research aids in the design of novel anti-angiogenic drugs, including monoclonal antibodies and small molecule inhibitors, which aim to block VEGFR-2 signaling and inhibit tumor angiogenesis. Additionally, studying VEGFR-2 can help in the exploration of potential biomarkers for disease prognosis and treatment responses. Overall, the ongoing research on VEGFR-2 recombinant proteins holds great promise for advancing cancer therapies and improving clinical outcomes for patients with angiogenesis-related diseases.
